What is the current share price of Mankind Pharma Limited (MANKIND)?

As of the latest market update, Mankind Pharma Limited (MANKIND) is trading at ₹2,381.1. The stock has moved 0.35% up in the recent session.

What is the technical sentiment for MANKIND stock?

Based on our proprietary technical analysis, the current signal for MANKIND is "NEUTRAL". This analysis considers over 20+ indicators including RSI, MACD, and moving average crossovers to gauge market momentum.

What is the 52-week high and low for Mankind Pharma Limited?

Mankind Pharma Limited has seen a 52-week high of ₹2,716.5 and a 52-week low of ₹1,909.7. Comparing the current price to these levels helps investors understand the stock's relative valuation and volatility over the past year.

Which sector does Mankind Pharma Limited belong to?

Mankind Pharma Limited operates in the Healthcare sector, specifically within the Pharmaceuticals & Biotechnology industry. Its performance is often influenced by broader trends in the Healthcare segment.

What is the market capitalization of MANKIND?

Mankind Pharma Limited (MANKIND) has a market capitalization of approximately ₹98.29K Cr. This classifies it as a mid cap stock in the Indian market.

MANKIND

NSEF&O

Mankind Pharma Limited (MID CAP)

Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals

₹2,381.10

8.40 (0.35%)

High VOLATILITY

As on 12 Jun 2026

Advanced Chart

Price History

Market Cap

The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.

₹98.29K Cr

MID CAP

P/E Ratio

Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.

50.9

Industry

The specific business sector the company operates in. Useful for comparing with similar companies.

Pharmaceuticals

52-Week Range

The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.

52W Low₹1,909.7+24.7%

52W High₹2,716.5-12.3%

Current Price

₹2,381.10

Circuit Limits (20%)

The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.

Lower Circuit₹1,904.88

Upper Circuit₹2,857.32

Reference Price

₹2,381.10

Investment Checklist

Double Top on 1W (BREAKOUT CONFIRMED) — target ₹2103.5

Triple Top on 1D (BREAKOUT CONFIRMED) — target ₹2103.5

Trend: Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)

Volume divergence: Bearish (price up, volume down)

News: Bernstein backs Zydus, Lupin and Sun Pharma on innovation shift...

Technical Analysis

Analysis from 2026-06-12

Confidence

44%

Trend

BULLISH

Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)

EMA20

2377.95

EMA50

2318.2

EMA200

2301.32

Price Action

MIXED

NEUTRAL

Higher Highs5

Higher Lows6

Lower Highs4

Lower Lows3

Support & Resistance Levels

Resistance (Above)

₹2426.44

₹2509.93

₹2650.10

₹2716.50

Support (Below)

₹2282.83

₹2204.83

₹2146.20

₹2099.15

₹2046.07

Volume Analysis

TrendDECREASING

Change-66.60%

Unusual VolumeNo

Divergence Detected

Bearish (price up, volume down)

Stop Loss Levels

Fixed Risk

1% Risk₹2357.29

3% Risk₹2309.67

5% Risk₹2262.04

7% Risk (Custom)

₹2214.42

Technical Levels

1x ATR (Volatility)₹2312.85

2x ATR (Swing)₹2244.60

3x ATR (Trend)₹2176.35

Immediate Support₹2282.83

Moving Averages

EMA 9 (Short-term)₹2375.16

EMA 20 (Medium-term)₹2377.95

EMA 50 (Trend)₹2318.20

EMA 200 (Long-term)₹2301.32

Financials

Financial Analysis

Metric	Dec '24	Mar '25	Jun '25	Dec '25
Revenue	₹3,198.8 Cr	₹3,007.5 Cr	₹3,570.4 Cr	₹3,567.2 Cr
Net Profit	₹380.2 Cr	₹420.8 Cr	₹438.3 Cr	₹408.8 Cr
EPS	₹9.45	—	₹10.62	₹9.90
Operating Profit	₹896.4 Cr	₹899.6 Cr	₹929.8 Cr	₹888.8 Cr

Peer Comparison

Pharmaceuticals

Peer Comparison

Symbol	Name	Price	Change
SUNPHARMA	Sun Pharmaceutical Industries Limited	₹1,807.70	+0.75%
DIVISLAB	Divi's Laboratories Limited	₹6,638.00	-0.26%
TORNTPHARM	Torrent Pharmaceuticals Limited	₹4,571.20	-0.02%
CIPLA	Cipla Limited	₹1,389.40	+0.44%
ZYDUSLIFE	Zydus Lifesciences Limited	₹1,104.70	-0.11%
DRREDDY	Dr. Reddy's Laboratories Limited	₹1,275.40	-0.05%
LUPIN	Lupin Limited	₹2,293.30	+0.88%
AUROPHARMA	Aurobindo Pharma Limited	₹1,472.80	+0.59%
LAURUSLABS	Laurus Labs Limited	₹1,394.30	+0.25%
BIOCON	Biocon Limited	₹419.00	+0.73%

Corporate Information

Large Deals

View All

Bulk, Block and Short deals reported for this stock.

Loading Deals...

Corporate Actions

Recent actions

View All

Ex Date	Purpose	Type
08 Aug 2025	Interim Dividend - Re 1 Per Share	INTERIM_DIVIDEND

Announcements

Latest updates

View All

Date	Description	Link
10 Jun 2026	Disclosure under SEBI Takeover Regulations
09 Jun 2026	Cessation
09 Jun 2026	Appointment
08 Jun 2026	Allotment of Securities
02 Jun 2026	Acquisition

Board Meetings

Upcoming and past meetings

View All

Date	Purpose	Links
19 May 2026	Financial Results
19 May 2026	Board Meeting Intimation
03 Feb 2026	Board Meeting Intimation	XBRL
03 Feb 2026	Financial Results
06 Nov 2025	Board Meeting Intimation	XBRL

Corporate Events

Upcoming results & meetings

View All

No upcoming events found

We couldn't find any scheduled corporate actions for this symbol at the moment.

Shareholding Pattern

As of Dec 2025

Current Distribution

Trend (Last 8 Qtrs)

Latest News

News for MANKIND

View All

Bernstein backs Zydus, Lupin and Sun Pharma on innovation shift

positive

CNBC TV18 - Markets 3d ago

Bernstein backs Zydus, Lupin and Sun Pharma on innovation shift

Nandan Kulkarni, Director–India Healthcare & Senior Research Analyst at Bernstein, sees strong opportunities in CDMOs, specialty therapies, biosimilars and licensing deals. While favouring Zydus, Lupin and Sun Pharma, he remains cautious on Biocon and Mankind Pharma, and argues that India's shift from generics to innovation could drive the next phase of growth for the pharma industry.

ABSLNN50ETBIOCONBSLGOLDETFHCGHCG-REHEALTHCAREHEALTHYLUPINMANKINDONESOURCESPARCFinancial ServicesHealthcare

Read full story

Stock Picks Today: Adani Ports, Hindalco, Mankind Pharma, Minda Corp, L&T On Brokerages' Radar

positive

NDTV Profit 5d ago

Stock Picks Today: Adani Ports, Hindalco, Mankind Pharma, Minda Corp, L&T On Brokerages' Radar

Check out top stocks under brokerages' radar heading into trade today.

ADANIENTADANIPORTSHINDALCOMANKINDMINDACORPAutomobile and Auto ComponentsHealthcare

Read full story

Ipca Laboratories among 5 stocks showing bullish RSI upswing

positive

ET Markets - Stocks 9d ago

Ipca Laboratories among 5 stocks showing bullish RSI upswing

Five Nifty500 stocks, including Leela Palaces, Eris Lifesciences, Indian Bank, Mankind Pharma, and Ipca Laboratories, showed bullish momentum as their RSI crossed above 50, signaling potential upward price movement.

BANKINDIAEMULTIMQERISINDIANBIOBIPCALABMANKINDMOMENTUMSOUTHBANKTHELEELAConsumer ServicesFinancial Services

Read full story

MANKIND

Price History

Investment Checklist

Technical Analysis

Technical Analysis

Trend

Price Action

Support & Resistance Levels

Volume Analysis

Stop Loss Levels

Fixed Risk

Technical Levels

Moving Averages

Financials

Financial Analysis

Peer Comparison

Peer Comparison

Corporate Information

Large Deals

Corporate Actions

Announcements

Board Meetings

Corporate Events

Shareholding Pattern

Shareholding Pattern

Current Distribution

Trend (Last 8 Qtrs)

Latest News

News for MANKIND

Bernstein backs Zydus, Lupin and Sun Pharma on innovation shift

Stock Picks Today: Adani Ports, Hindalco, Mankind Pharma, Minda Corp, L&T On Brokerages' Radar

​Ipca Laboratories among 5 stocks showing bullish RSI upswing

Frequently Asked Questions

What is the current share price of Mankind Pharma Limited (MANKIND)?

What is the technical sentiment for MANKIND stock?

What is the 52-week high and low for Mankind Pharma Limited?

Which sector does Mankind Pharma Limited belong to?

What is the market capitalization of MANKIND?

Ipca Laboratories among 5 stocks showing bullish RSI upswing